SS-31

SS-31 targets the inner mitochondrial membrane, where it binds to cardiolipin, a phospholipid essential for maintaining mitochondrial structure and function. By stabilizing cardiolipin, SS-31 helps to preserve the integrity of the mitochondrial membrane and enhances the efficiency of the electron transport chain. This, in turn, reduces the production of reactive oxygen species (ROS) and improves overall mitochondrial function.

Additionally, SS-31 has been shown to modulate various signaling pathways involved in inflammation, apoptosis, and cellular stress responses. It can inhibit the activation of pro-inflammatory cytokines, such as TNF-α and IL-1β, and reduce the expression of apoptotic markers, like caspase-3 and Bax. SS-31 also promotes the activation of pro-survival pathways, including the PI3K/Akt and MAPK/ERK signaling cascades, which contribute to its cytoprotective effects.

• Neuroprotection: SS-31 has demonstrated neuroprotective properties in various animal models of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. It can reduce oxidative stress, inflammation, and mitochondrial dysfunction in the brain, leading to improved cognitive function and reduced neuronal damage.

• Cardioprotection: Studies have shown that SS-31 can protect the heart from ischemia-reperfusion injury, reduce cardiac hypertrophy, and improve cardiac function in models of heart failure. By preserving mitochondrial function and reducing oxidative stress, SS-31 may have potential therapeutic applications in cardiovascular diseases.

• Anti-aging effects: SS-31 has been investigated for its potential to attenuate age-related changes in various tissues, including the heart, skeletal muscle, and brain. It can reduce age-associated post-translational modifications of proteins, improve mitochondrial function, and enhance cellular resilience, suggesting its potential as an anti-aging intervention.

• Mitochondrial myopathy: In a randomized clinical trial (MMPOWER-3), SS-31 demonstrated efficacy and safety in individuals with primary mitochondrial myopathy. The peptide improved exercise tolerance, walking distance, and overall quality of life in patients, highlighting its potential as a treatment for mitochondrial disorders.

• Retinal diseases: SS-31 has shown promise in preclinical studies for the treatment of age-related macular degeneration (AMD) and other retinal disorders. By reducing oxidative stress and preserving mitochondrial function in the retina, SS-31 may help to prevent or slow the progression of these diseases.

In clinical trials and preclinical studies, SS-31 has been generally well-tolerated, with no significant adverse effects reported. However, as with any investigational compound, further research is needed to fully evaluate its safety profile and potential long-term side effects.

SS-31 (elamipretide) is a mitochondrially-targeted peptide that has shown promising therapeutic potential in various research studies. By stabilizing cardiolipin, reducing oxidative stress, and modulating inflammatory and apoptotic pathways, SS-31 can protect against mitochondrial dysfunction and cellular damage. Its neuroprotective, cardioprotective, and anti-aging properties make it a potential candidate for the treatment of age-related and neurodegenerative disorders, as well as mitochondrial myopathies and retinal diseases. While further clinical studies are needed to fully evaluate its efficacy and safety, SS-31 represents an exciting avenue for the development of novel therapies targeting mitochondrial dysfunction.

1. Obi C, Smith AT, Hughes GJ, Adeboye AA. Targeting mitochondrial dysfunction with elamipretide. Heart Fail Rev. 2022

2. Zhao W, Xu Z, Cao J, Fu Q, Wu Y, Zhang X, Long Y, Zhang X, Yang Y, Li Y, Mi W. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation. 2019

3. Zhang H, Chen Y, Li F, Wu C, Cai W, Ye H, Su H, He M, Yang L, Wang X, Zhou K, Ni W. Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization. J Neuroinflammation. 2023

4. Karaa A, Bertini E, Carelli V, Cohen BH, Enns GM, Falk MJ, Goldstein A, Gorman GS, Haas R, Hirano M, Klopstock T, Koenig MK, Kornblum C, Lamperti C, Lehman A, Longo N, Molnar MJ, Parikh S, Phan H, Pitceathly RDS, Saneto R, Scaglia F, Servidei S, Tarnopolsky M, Toscano A, Van Hove JLK, Vissing J, Vockley J, Finman JS, Brown DA, Shiffer JA, Mancuso M; MMPOWER-3 Trial Investigators. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023

5. Nhu NT, Xiao SY, Liu Y, Kumar VB, Cui ZY, Lee SD. Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration. Front Integr Neurosci. 2022

6. Whitson JA, Martín-Pérez M, Zhang T, Gaffrey MJ, Merrihew GE, Huang E, White CC, Kavanagh TJ, Qian WJ, Campbell MD, MacCoss MJ, Marcinek DJ, Villén J, Rabinovitch PS. Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins. Geroscience. 2021

7. Jiang W, He F, Ding G, Wu J. Elamipretide reduces pyroptosis and improves functional recovery after spinal cord injury. CNS Neurosci Ther. 2023

8. Sabbah HN. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide. Heart Fail Rev. 2021

9. Campbell MD, Martín-Pérez M, Egertson JD, Gaffrey MJ, Wang L, Bammler T, Rabinovitch PS, MacCoss M, Qian WJ, Villen J, Marcinek D. Elamipretide effects on the skeletal muscle phosphoproteome in aged female mice. Geroscience. 2022

10. Nashine S. Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD). Cells. 2021

11. Chatfield KC, Sparagna GC, Chau S, Phillips EK, Ambardekar AV, Aftab M, Mitchell MB, Sucharov CC, Miyamoto SD, Stauffer BL. Elamipretide Improves Mitochondrial Function in the Failing Human Heart. JACC Basic Transl Sci. 2019

12. Zuo Y, Yin L, Cheng X, Li J, Wu H, Liu X, Gu E, Wu J. Elamipretide Attenuates Pyroptosis and Perioperative Neurocognitive Disorders in Aged Mice. Front Cell Neurosci. 2020